Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915912 | 0.84 | OPRM1 (0.48) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL10564558 | 0.82 | CYP2D6 (0.37) | KCNH2CHRM4CYP2D6CHRM3KMT2A | |
| SCHEMBL7486355 | 0.77 | OPRM1 (0.44) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL1221934 | 0.77 | KMT2A (0.49) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL1733204 | 0.76 | KMT2A (0.43) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL21848133 | 0.76 | CHRM4 (0.46) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL13778883 | 0.76 | CYP2D6 (0.44) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL13778878 | 0.76 | KMT2A (0.50) | CYP2D6CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL14141052 | 0.76 | OPRM1 (0.41) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL13778885 | 0.75 | CCR5 (0.47) | CYP2D6CACNA2D1CACNA1BCACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078161-B2 | Rock-inhibiting compound and uses thereof | HITGEN INC. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200190035-A1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | HITGEN INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-8207355-B2 | Method for preparing azetidine derivatives | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-8071788-B2 | Method and intermediates for the preparation of derivatives of N-(1-benzhydrylazetidin-3-yl)-N-phenylmethylsulfonamide | SANOFI-AVENTIS (FR) | 2011-12-06 | — | — | US | disclosed |
| US-20110118481-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20100087414-A1 | METHOD AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N (1-BENZHYDRYLAZETIDIN-3-YL)-N-PHENYLMETHYLSULFONAMIDE | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| US-7652154-B2 | Method and intermediates for the preparation of derivatives of N (1-benzhydrylazetidin-3-yl)-N-phenylmethylsulfonamide | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| US-20080312205-A1 | METHOD AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N (1-BENZHYDRYLAZETIDIN-3-YL)-N-PHENYLMETHYLSULFONAMIDE | SANOFI-AVENTIS (FR) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078161-B2 | Rock-inhibiting compound and uses thereof | ROCK1, ROCK2, RHOA | OPRM1 4230/4885CHRM2 1145/4885ADRA2A 2028/4885 |
| US-20200190035-A1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | ROCK1, ROCK2, RHOA | OPRM1 4230/4885CHRM2 1145/4885ADRA2A 2028/4885 |
| US-20100087414-A1 | METHOD AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N (1-BENZHYDRYLAZETIDIN-3-YL)-N-PHENYLMETHYLSULFONAMIDE | NPEPPS, DHPS, NISCH | OPRM1 3159/4885CHRM2 3934/4885ADRA2A 4191/4885 |
| US-20080312205-A1 | METHOD AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N (1-BENZHYDRYLAZETIDIN-3-YL)-N-PHENYLMETHYLSULFONAMIDE | NPEPPS, DHPS, NISCH | OPRM1 3159/4885CHRM2 3934/4885ADRA2A 4191/4885 |
| US-20110118481-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | QDPR, AZI2, NISCH | OPRM1 2538/4885CHRM2 2313/4885ADRA2A 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.